Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. Using breakthrough piezo-print technology for high-precision micro-dosing and the first smart electronic mobile health compliance tracking platform for topical pharmaceuticals, Eyenovia is building a premier eye care company of the future. The company is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. Eyenovia is building a portfolio of superior micro-therapeutics with its proprietary piezo-formulations of existing and new molecular entities.
- 0.24 (2.83%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference
Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
|06/20/18 1:30 p.m. ET|
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(718) 921-8124 (phone)
(718) 921-8386 (fax)